Patients with high-risk local melanomas benefit from immunotherapy drug: Study \
5 min read
\
\

Patients with high-risk local melanomas benefit from immunotherapy drug: Study

20-Sep-2021
Pennsylvania [US], September 20 (ANI): According to the results of an international, randomized phase III clinical trial led by UPMC Hillman Cancer Center, immunotherapy called pembrolizumab reduced cancer recurrence after surgery in patients with stage IIb and IIc melanoma.
20-Sep-2021 Science
\